Abstract:ID 92395 Poster Board 511 Opioid Use Disorder (OUD) is a chronic, relapsing disease that, despite our best research efforts, has become a worsening public health crisis. Currently, the medications to treat OUD belong to the opioid class of drugs and, therefore, continue to interact directly with opioid receptors. While these medications are safe and effective for the cessation of opioids with higher abuse potentials, there is still a need for effective non-opioid receptor-targeting therapeutics. Exploring novel non-opioid targets is necessary to overcome this barrier. One such non-opioid target we are currently investigating is the calcitonin gene-related peptide (CGRP) system, particularly CGRP-expressing neurons in the parabrachial nucleus (CGRP PBN ). These neurons have been well studied in itch and pain and are known to project to brain regions implicated in opioid reward and withdrawal. Previous studies in our lab have found that CGRP PBN activity decreases during opioid taking and increases during opioid withdrawal. To further characterize the behavioral role of CGRP PBN neurons in opioid withdrawal, Calca-Cre transgenic mice received viral injections into the PBN containing an inhibitory DREADD (hm4Di), and two weeks later, mice were implanted with 2x25 mg morphine pellets. After five days, morphine withdrawal was induced by removing the pellets. Mice were administered either clozapine-N-oxide (CNO) (3 mg/kg, I.P.) or vehicle (saline, I.P.) 5.5 hours post pellet removal, and behavior was recorded at 6 and 24 hours post pellet removal. Two experimenters scored videos for jumping and wet dog shakes. Those mice injected with CNO showed fewer wet-dog shakes at the 6-hour time than vehicle-injected controls. We next sought to characterize the behavioral role of CGRP PBN neurons in opioid taking. In this experiment, morphine intravenous self-administration (IVSA) was used. Calca-Cre transgenic mice received viral injections into the PBN containing either an inhibitory DREADD (hm4Di) or a control mCherry vector and, two weeks later, were implanted with jugular catheters. Subsequently, operant responding for intravenous morphine was established. After 12 daily sessions, mice were administered CNO (3 mg/kg, I.P.) or vehicle (saline, I.P.) and allowed to respond for morphine. CGRP PBN inhibition reduced morphine intake in hm4Di-injected animals, while those with a control virus maintained their previous levels of morphine intake. Decreases in morphine intake were maintained 24 hours after CNO administration but returned to previous baseline levels at 48 hours. These results suggest that CGRP PBN neurons play a role in the behavioral consequences of both opioid reinforcement and withdrawal. CGRP receptor inhibitors are FDA-approved for the treatment of migraine and exist in both short and long-lasting formulations. By leveraging these available medications for the off-label purpose of treating OUD, we may be able to determine the translational potential of these preclinical findings and, therefore, expand our therapeutic arsenal for long-term maintenance of opioid abstinence and relapse.

Acute and Chronic Bupropion Treatment Does Not Prevent Morphine-Induced Conditioned Place Preference in Mice.

Preclinical evidence for the use of the atypical antipsychotic, brexpiprazole, for opioid use disorder

Reactivation of Morphine Conditioned Place Preference by Drug Priming: Role of Environmental Cues and Sensitization

Inhibition of the Reinstatement of Morphine-Induced Place Preference in Rats by High-Frequency Stimulation of the Bilateral Nucleus Accumbens.

Inhibition of Phosphodiesterase10a Attenuates Morphine-Induced Conditioned Place Preference.

Dezocine Alleviates Morphine-Induced Dependence in Rats

Roles of Dopaminergic Innervation of Nucleus Accumbens Shell and Dorsolateral Caudate-Putamen in Cue-Induced Morphine Seeking after Prolonged Abstinence and the Underlying D1- and D2-like Receptor Mechanisms in Rats

Inhibition of Parabrachial CGRP Neurons Reduces Morphine Reinforcement and Withdrawal

Dose- and Time-Dependent, Context-Induced Elevation of Dopamine and Its Metabolites in the Nucleus Accumbens of Morphine-Induced CPP Rats

Morphine Exposure Reduces Nicotine-Induced Upregulation of Nicotinic Receptors and Decreases Volitional Nicotine Intake in a Mouse Model

The Effects of Chronic Naltrexone on Reinstatement of Opioid-Induced Drug-Seeking Behavior and Antinociception

Mesoaccumbens Dopamine Signaling Alteration Underlies Behavioral Transition from Tolerance to Sensitization to Morphine Rewarding Properties During Morphine Withdrawal

Intra-nucleus Accumbens Shell Injection of Baclofen Blocks the Reconsolidation of Conditioned Place Preference in Morphine-Addicted Mice

Inhibition of PSD95‐nNOS protein–protein interactions decreases morphine reward and relapse vulnerability in rats

The differential effects of OX1R and OX2R selective antagonists on morphine conditioned place preference in naïve versus morphine-dependent mice

Dorsal hippocampal NMDA receptor blockade impairs extinction of naloxone-precipitated conditioned place aversion in acute morphine-treated rats by suppressing ERK and CREB phosphorylation in the basolateral amygdala.

Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine

Chronic Morphine Treatment Switches The Effect Of Dopamine On Excitatory Synaptic Transmission From Inhibition To Excitation In Pyramidal Cells Of The Basolateral Amygdala

Blockade of Cannabinoid CB1 Receptor Attenuates the Acquisition of Morphine-Induced Conditioned Place Preference along with a Downregulation of ERK, CREB Phosphorylation, and BDNF Expression in the Nucleus Accumbens and Hippocampus.

Intra-nucleus-accumbens SKF38393 Improved the Impaired Acquisition of Morphine-Conditioned Place Preference in Depression-Like Rats.

BDNF-AAV has protective effects on morphine-induced conditioned place preference through BDNF, TrkB, and CREB concentration changes in the VTA and NAc